We want to understand what are the very earliest forms of coronary disease. We seek answers to questions such as what is different about the people that end up having plaque buildup and those who don’t? We know that diabetes, hypertension and cholesterol typically become abnormal decades after the CHD sets in, so we will investigate further upstream for approaches that can delay or prevent onset. We will also look for novel lifestyle and behavioral modification approaches that can be difference-makers.
These are lofty goals and they wouldn’t be possible without challenging current research funding paradigms and embracing new ways to do science. Our aim is to create a nimble, entrepreneurial structure, similar to that of a start-up company. Our investigators know they will likely come to dead ends. That’s OK. Every effort will provide meaningful information – even if the answer is to look somewhere else.
About the Team:
Led by Calum MacRae, chief of cardiovascular medicine at Brigham and Women’s Hospital (BWH), the One Brave idea team is comprised of world-renowned investigators from a wide variety of specialties like engineering and data scientists from institutions including MIT and Stanford. Each has experience breaking down boundaries and working outside the constraints of traditional biomedical science.
The team will work out of The One Brave Idea Science Innovation Center in Boston to facilitate new techniques in a clinical context. Here they will have access to a national consortium of translational scientists, engineering expertise of MIT and the clinical device expertise of BWH’s Next Generation Phenotyping Center.